Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Zonegran

- PMLiVE

Eisai ‘outraged’ by IQWIG’s failure to back epilepsy drug

German cost-effectiveness body once again says Fycompa should not be reimbursed

- PMLiVE

Eisai names new US financial head

Barry Lederman joins as chief financial officer

- PMLiVE

Epilepsy takes centre stage in UK

National Epilepsy Week aims to raise awareness of the neurological condition

- PMLiVE

Eisai resubmits Fycompa to G-BA for pricing assessment

But German distribution of epilepsy drug remains on hold until reimbursement settled

Biogen Idec building

Eisai and Biogen partner on Alzheimer’s

Will co-develop two drug candidates

- PMLiVE

Germany looks again at Fycompa pricing

Eisai's epilepsy drug could be re-entered onto market

- PMLiVE

UCB files Vimpat for expanded epilepsy use

Submits monotherapy application to FDA


- PMLiVE

Eisai doubles Belviq’s US sales force

Will take on more than 200 new contact sales reps to promote obesity drug

- PMLiVE

Eisai expands in Europe with new Belgium business

Will coordinate local reimbursement for cancer drug Halaven

- PMLiVE

Eisai launches Halaven in Russia

Expands market reach of its breast cancer drug to cover emerging market

- PMLiVE

Eisai lines-up Fycompa access programme for Germany

But sales suspension for epilepsy drug will continue

- PMLiVE

Eisai launches online obesity awareness drive

Wants US employers to realise the cost of obesity

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links